Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 38Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 9Waldenstrom Macroglobulinemia 8Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Mantle-Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, Myeloid, Acute 4Leukemia 4Lymphoma, Large B-Cell, Diffuse 3Neoplasm Metastasis 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, B-Cell 2Hodgkin Disease 2Thrombocytosis 1Signs and Symptoms, Digestive 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoid Malignancies 1Leukemia, Prolymphocytic 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma × idelalisib × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04699461 2023-10-23

LOTIS-6

ADC Therapeutics S.A.

Phase 2 Terminated
6 enrolled 9 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT01796470 2020-06-02

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Gilead Sciences

Phase 2 Terminated
66 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00710528 2012-08-31

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Gilead Sciences

Phase 1 Completed
192 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡